- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05651503
The Effect of Oral Probiotics on Oral Hygiene and Halitosis in Orthodontic Patients.
The Effect of Oral Probiotics on Oral Hygiene and Halitosis in Orthodontic Patients: a Randomized Controlled Trial
Brackets, bands, ligatures and wires in patients receiving orthodontic treatment with fixed appliances are areas that trap food and impede oral hygiene. An ecological environment facilitating the growth of microorganisms (Actinobacillus, Bacteroides, Prevotella etc.) emerges in the mouth and may cause caries, enamel white spots, gingival inflammation and halitosis. Despite the use of specialized orthodontic brushes, interdental brushes, mouthwashes and topical fluorides, plaque removal remains inadequate in patients with fixed orthodontic appliances. On the other hand, patients undergoing orthodontic treatment with aligners have been found to have better oral hygiene because of less plaque accumulation in their mouth.
Probiotics are defined as non-pathogenic bacteria that can benefit the host's general health when taken in sufficient amounts through nutrition. Nowadays probiotics can be used to enhance oral health as they are found to reduce dental biofilm formation, prevent and decrease halitosis in children, adolescents and adults. To date, there are few randomized controlled trials (RCTs) examining the efficacy of oral probiotics in patients with fixed orthodontic appliances and none reporting the incidence of halitosis and the effect of probiotics in orthodontic patients wearing aligners.
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Attica
-
Athens, Attica, Greece, 11527
- National and Kapodistrian University of Athens, School of Dentistry, Departments of Orthodontics
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients eligible for the trial must comply with all of the following at randomization:
- Age between 12 and 18 years for the group with conventional orthodontic appliances This age group represents the majority of patients seeking orthodontic treatment and is homogeneous regarding occupational status (high-school and lyceum students in Greece). Younger patients might present with cooperation problems.
Age ≥18 for the Invisalign™ group This age group represents the majority of patients seeking orthodontic with aligners (Invisalign™) regarding social status and other factors.
- Good general health
- Fixed orthodontic appliances Patients should have fixed labial appliances (brackets) on all teeth from central incisor to first molar, in both the maxillary and the mandibular arch. Fixed appliances should have been placed at least two months before the patient is accepted into the study and remaining treatment should be at least 3 months. All brackets will be the same (metallic, conventional/not self-ligating, same size). Molars should be banded (same bands on all molars) and all other teeth bonded.
- At least 20 natural teeth (in case of extraction orthodontic treatment patients can be enrolled two months after extractions) The outcomes will be evaluated at all teeth from first molar to first molar.
Exclusion Criteria:
Patients will be excluded for any of the following reasons:
- Active caries
- Periodontitis
- Syndromes, mental disabilities and craniofacial deformities
- Smoking or use of other tobacco products
- Dental fluorosis/tooth malformation
- Antibiotics during the last 2 months
- chlorhexidine in the previous 3 week
- Suffering from any disease within 2 months before measurements
- Allergy to dairy products
- Participation in other trials Consent / assent Parents/guardians and patients will provide written informed consent and patients will provide written assent before randomization and before any procedures are applied.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Experimental group 1: patients, age 12-18, conventional brackets, Oral probiotics lozenges
30 patients, age 12-18,with conventional brackets,will get Oral probiotics lozenges
|
In our study oral probiotics Lactobacillus salivarius Oral S1 11 (Prodilac Oral, Frezyderm) will be tested in two Experimental groups
|
|
Experimental: Experimental group 2: patients, age ≥18, Invisalign™ appliances, Oral probiotics lozenges
30 patients, age ≥18, Invisalign™ appliances,wil get Oral probiotics lozenges
|
In our study oral probiotics Lactobacillus salivarius Oral S1 11 (Prodilac Oral, Frezyderm) will be tested in two Experimental groups
|
|
Placebo Comparator: Control group 1: patients, age 12-18, conventional brackets, placebo lozenges
30 patients, age 12-18, conventional brackets,will get placebo lozenges
|
In order to avoid possible bias, probiotics will be compared with placebo lozenges/no probiotic in two Control groups
|
|
Placebo Comparator: Control group 2: patients, age ≥18, Invisalign™ appliances, placebo lozenges
30 patients, age ≥18, Invisalign™ appliances,will get placebo lozenges
|
In order to avoid possible bias, probiotics will be compared with placebo lozenges/no probiotic in two Control groups
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Modified Silness and Löe plaque index (PI-M)
Time Frame: baseline-1 month
|
The Silness and Löe index does not take into account the pattern of plaque accumulation in orthodontic patients.
To overcome this problem, divided the tooth into mesial, distal, gingival, and incisal regions in relation to the bracket and scored plaque in each region using the four codes of the original index (0 to 3).
The values are summed to obtain a total score, which ranges from 0 to 12 for each tooth.
This modified index is recommended for patients with fixed orthodontic appliances because it acknowledges the usual effects of orthodontic appliances on plaque distribution and has much greater categorical discrimination.
|
baseline-1 month
|
|
Modified Silness and Löe plaque index (PI-M)
Time Frame: 1 month- 3 month
|
The Silness and Löe index does not take into account the pattern of plaque accumulation in orthodontic patients.
To overcome this problem, divided the tooth into mesial, distal, gingival, and incisal regions in relation to the bracket and scored plaque in each region using the four codes of the original index (0 to 3).
The values are summed to obtain a total score, which ranges from 0 to 12 for each tooth.
This modified index is recommended for patients with fixed orthodontic appliances because it acknowledges the usual effects of orthodontic appliances on plaque distribution and has much greater categorical discrimination.
|
1 month- 3 month
|
|
Modified Gingival index (GI-M)
Time Frame: baseline-1 month
|
The Gingival Index (GI) is a measure of the severity of gingivitis and is scored by measuring the amount of gingival inflammation, also considering redness and bleeding .
|
baseline-1 month
|
|
Modified Gingival index (GI-M)
Time Frame: 1 month- 3 month
|
The Gingival Index (GI) is a measure of the severity of gingivitis and is scored by measuring the amount of gingival inflammation, also considering redness and bleeding.
|
1 month- 3 month
|
|
Halitosis/ VSCs levels
Time Frame: baseline-1 month
|
VSCs levels will recorded at each time point with the use of OralChromaTM.
OralChromaTM is a portable gas chromatograph, which uses ambient air as a carrier gas and a semiconductor (In2O3) gas sensor to detect volatile sulphur compounds (VSCs), i.e. the concentrations of H2S, CH3SH and (CH3)2S.
|
baseline-1 month
|
|
Halitosis/ VSCs levels
Time Frame: 1 month- 3 month
|
VSCs levels will recorded at each time point with the use of OralChromaTM.
OralChromaTM is a portable gas chromatograph, which uses ambient air as a carrier gas and a semiconductor (In2O3) gas sensor to detect volatile sulphur compounds (VSCs), i.e. the concentrations of H2S, CH3SH and (CH3)2S.
|
1 month- 3 month
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Iosif Sifakakis, Associate Professor, University of Athens
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 444/27.07.2020
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Probiotics
-
Sanjay Gandhi Postgraduate Institute of Medical...Indian Council of Medical ResearchCompleted
-
The Affiliated Hospital of Qingdao UniversityPeking University People's Hospital; Cancer Institute and Hospital, Chinese... and other collaboratorsRecruitingProbiotics | Colorectal AdenomaChina
-
Cheng-Hsin General HospitalCompleted
-
Taipei Medical University Shuang Ho HospitalTaipei Medical University; Delta ElectronicsUnknownProbiotics | Vancomycin-Resistant EnterococciTaiwan
-
Chr HansenUniversity of Copenhagen; Herlev HospitalCompleted
-
University of California, San DiegoActive, not recruiting
-
Mackay Memorial HospitalBened Biomedical Co., Ltd.Completed
-
Stanford UniversityCompleted
-
Texas Christian UniversityCompleted
-
University of TurkuUniversity of Michigan; The Forsyth InstituteCompleted
Clinical Trials on Probiotics
-
Glac Biotech Co., LtdCompletedMetabolic SyndromeTaiwan
-
University of Milano BicoccaCompleted
-
Chung Shan Medical UniversityNutrarex Biotech Ltd.Recruiting
-
Wecare Probiotics Co., Ltd.Not yet recruiting
-
Arkansas Children's Hospital Research InstituteCompleted
-
Chr HansenAarhus University HospitalCompletedInfant Development | Gut MicrobiomeDenmark
-
Zealand University HospitalHolbaek Sygehus; Chr Hansen; Dept. of Microbiology, Slagelse University Hospital... and other collaboratorsCompleted
-
National Cheng-Kung University HospitalNational Science Council, TaiwanUnknownGastrointestinal Function | Intestinal Bacteria FloraTaiwan
-
TCI Co., Ltd.Active, not recruiting
-
Glac Biotech Co., LtdCompletedProbiotics | Oral Health | Probiotic MetabolitesTaiwan